Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-α-methyl tyrosine uptake in outcome of non-small cell lung cancer.

[1]  David J. Yang,et al.  Synthesis of isomers of 18F‐labelled amino acid radiopharmaceutical: Position 2− and 3‐L‐18F-α‐methyltyrosine using a separation and purification system , 1997, Nuclear medicine communications.

[2]  Y. Kanai,et al.  Expression of L‐type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models , 2001, Journal of surgical oncology.

[3]  N. Sunaga,et al.  L‐type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non‐small cell lung cancer , 2009, Histopathology.

[4]  J Aoki,et al.  Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study. , 2001, Radiology.

[5]  Tomio Inoue,et al.  18F α-methyl tyrosine PET studies in patients with brain tumors , 1999 .

[6]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[7]  N. Sunaga,et al.  CD98 Expression Is Associated with Poor Prognosis in Resected Non-Small-Cell Lung Cancer with Lymph Node Metastases , 2009, Annals of Surgical Oncology.

[8]  H. Christensen,et al.  Role of amino acid transport and countertransport in nutrition and metabolism. , 1990, Physiological reviews.

[9]  Keigo Endo,et al.  Present role and future prospects of positron emission tomography in clinical oncology , 2006, Cancer science.

[10]  T. Shibasaki,et al.  Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  Y Kanai,et al.  Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer , 2008, British Journal of Cancer.

[12]  J Aoki,et al.  Accuracy of standardized uptake value measured by simultaneous emission and transmission scanning in PET oncology. , 1999, Nuclear medicine communications.

[13]  Keigo Endo,et al.  18F-FMT Uptake Seen Within Primary Cancer on PET Helps Predict Outcome of Non–Small Cell Lung Cancer , 2009, Journal of Nuclear Medicine.

[14]  N. Sunaga,et al.  Correlation of angiogenesis with 18F‐FMT and 18F‐FDG uptake in non‐small cell lung cancer , 2009, Cancer science.

[15]  N. Sunaga,et al.  L‐type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas , 2009, Journal of surgical oncology.

[16]  D. Oxender,et al.  Evidence for two Types of Mediation of Neutral Amino-Acid Transport in Ehrlich Cells , 1963, Nature.

[17]  Eiji Takeda,et al.  Expression Cloning and Characterization of a Transporter for Large Neutral Amino Acids Activated by the Heavy Chain of 4F2 Antigen (CD98)* , 1998, The Journal of Biological Chemistry.

[18]  N. Sunaga,et al.  l‐type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms , 2008, Cancer science.

[19]  M. Pastor-Anglada,et al.  Regulatory and molecular aspects of mammalian amino acid transport. , 1994, The Biochemical journal.

[20]  Tomio Inoue,et al.  PET imaging of musculoskeletal tumours with fluorine-18 α-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET , 2000, European Journal of Nuclear Medicine.

[21]  Takashi Nakajima,et al.  Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study , 2007, Clinical Cancer Research.

[22]  N. Sunaga,et al.  Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. , 2009, Lung cancer.

[23]  K. Nakanishi,et al.  LAT1 expression in non-small-cell lung carcinomas: analyses by semiquantitative reverse transcription-PCR (237 cases) and immunohistochemistry (295 cases). , 2010, Lung cancer.

[24]  Y. Kanai,et al.  Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. , 2001, Biochimica et biophysica acta.

[25]  N. Sunaga,et al.  Prognostic significance of L‐type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung , 2009, Cancer science.

[26]  Takashi Nakajima,et al.  Evaluation of thoracic tumors with 18F‐FMT and 18F‐FDG PET‐CT: A clinicopathological study , 2009, International journal of cancer.

[27]  S. Alyafei,et al.  Fundamental study of hot spot detectability in 3-dimensional positron emission tomography , 2000, Annals of nuclear medicine.

[28]  H. Iijima,et al.  Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. , 2008, Pathology, research and practice.

[29]  Keigo Endo,et al.  Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. , 2007, Chest.